Ichnos Glenmark Innovation: Accelerating Cancer Drug Discovery

Glenmark Pharmaceuticals Ltd. (Glenmark), a research-focused global pharmaceutical company, and Ichnos Sciences Inc. (Ichnos), an international clinical technology subsidiary, announced the launch of its partnership, Ichnos Glenmark Innovation. They are accelerating drug discovery in cancer treatment. The partnership continues to develop therapeutics for treating hematologic malignancies and solid tumors by combining Glenmark's small molecule research with Ichnos' advanced biologics development and capabilities.

IGI has recently developed a strong pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors in clinical trials. Two of these molecules have received US orphan drug designation. FDA. IGI also has two autoimmune disease properties licensed to large companies.

IGI leverages the strengths of three global innovation centers, utilizing the combined skills of more than 150 scientists. These include Ichnos' headquarters in New York City, New York, USA, where the company focuses on clinical development. Center for Biological Research, Lausanne, Switzerland and Glenmark Small Molecule Research Center, Mahape, Mumbai, India.

“We are proud to announce the Ichnos Glenmark Innovation Alliance, which combines Glenmark's legacy with Ichnos' passion for accelerating cancer treatment research. Innovation is an integral part of our organizational structure, and we are confident that IGI will bring us one step closer to our goal of developing new cancer treatments for the world. This will enhance shareholder value by optimizing development costs," said Glenn Saldanha, president and CEO of Glenmark Pharmaceuticals Ltd. multi-characteristic pipeline assembly and small molecules.

Supported by experienced leadership and a team that believes firmly in the challenge of pioneering science, IGI will benefit from Glenmark's presence in India, its expertise and its capabilities. We look forward to joining like-minded organizations, including biotech companies and universities.".